

# SECURITIES AND EXCHANGE COMMISSION

## FORM 3

Filing Date: **2013-01-28** | Period of Report: **2013-01-28**  
SEC Accession No. [0000908662-13-000059](#)

(HTML Version on [secdatabase.com](http://secdatabase.com))

### REPORTING OWNER

#### Rowinsky Eric K

CIK: **1318886**

Type: **3** | Act: **34** | File No.: **001-35619** | Film No.: **13552860**

Mailing Address  
*IMCLONE SYSTEMS  
INCORPORATED  
180 VARICK STREET, 6TH  
FLOOR  
NEW YORK NY 10014*

### ISSUER

#### STEMLINE THERAPEUTICS INC

CIK: **1264587** | IRS No.: **450522567** | State of Incorp.: **DE** | Fiscal Year End: **1231**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
*750 LEXINGTON AVENUE  
NEW YORK NY 10022*

Business Address  
*750 LEXINGTON AVENUE  
NEW YORK NY 10022  
212-831-1111*

# FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	02/28/2011
Estimated average burden hours per response	0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person</b> <u>Rowinsky Eric K</u> (Last) (First) (Middle) C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR (Street) NEW YORK, NY 10022 (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 01/28/2013	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>STEMLINE THERAPEUTICS INC [STML]</u> <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> ___ Director ___ 10% Owner <u>X</u> Officer (give title below) ___ Other (specify below) <u>EVP, Chief Med. Off., Head R&amp;D</u> <b>5. If Amendment, Date Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check applicable line)</b> ___ Form Filed by One Reporting Person ___ Form Filed by More than One Reporting Person
---	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(L)	03/01/2022	Common Stock	112,202	\$3.3	D	

**Explanation of Responses:**

- The option vests as to 17,765 shares upon the closing of an initial public offering. Of the remaining shares, 25% vest on February 29, 2013, the first anniversary of the grant date, and the remaining 75% vest in approximately equal quarterly installments through the fourth anniversary of the grant date.

**Signatures**

/s/ Eric Rowinsky

\*\* Signature of Reporting Person

01/28/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**